Results 81 to 90 of about 109,274 (257)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Automated Driver Drowsiness Monitoring System

open access: yesInternational Research Journal on Advanced Engineering and Management (IRJAEM)
This presentation introduces an innovative end-to-end non-intrusive IoT-based automated frame work designed for logistic and public transport applications, aiming to address the exponential growth in road accidents. Leveraging behaviour analysis-based approaches and computer vision techniques, the framework detects and monitors driver behaviours such ...
null Dr. B. Saroja Ph. D   +5 more
openaire   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Low-Cost Driver Monitoring System Using Deep Learning

open access: yesIEEE Access
Driver monitoring systems are becoming an essential part of Advanced Driver Assistance Systems (ADAS) safety features in modern vehicles. The U.S. National Highway Traffic Safety Administration reports that drowsy/fatigued driving results in almost 100 ...
Hady A. Khalil   +3 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Deep Learning Model for Driver Behavior Detection in Cyber-Physical System-Based Intelligent Transport Systems

open access: yesIEEE Access
As Intelligent Transport Systems (ITS) continue to evolve, the quest for improving road safety and transportation efficiency has gained renewed emphasis.
Brij B. Gupta   +3 more
doaj   +1 more source

A Smartphone-Based Driver Safety Monitoring System Using Data Fusion

open access: yesSensors, 2012
This paper proposes a method for monitoring driver safety levels using a data fusion approach based on several discrete data types: eye features, bio-signal variation, in-vehicle temperature, and vehicle speed.
Wan-Young Chung, Boon-Giin Lee
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

On-Road Evaluation of an Unobtrusive In-Vehicle Pressure-Based Driver Respiration Monitoring System

open access: yesSensors
In-vehicle physiological sensing is emerging as a vital approach to enhancing driver monitoring and overall automotive safety. This pilot study explores the feasibility of a pressure-based system, repurposing commonplace occupant classification ...
Sparsh Jain, Miguel A. Perez
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy